Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus
Summary
To investigate the preliminary pharmacokinetics, pharmacodynamics, safety and tolerability of GW823093 at doses of 15mg and 30mg given once daily for 7 days in Japanese Type 2 diabetes mellitus (T2DM) patients.
Timeline
- Start
- 2006-03-22
- Primary completion
- 2006-06-28
- Completion
- 2006-06-28
Outcome
Mixed primary results
registry analysis (superiority or other test); Placebo vs GW823093C 15 mg; Mean Difference (Final Values) -2.10 (95% CI -2.28 to -1.93); Double-delta analysis NCT00372957 ↗
registry analysis (superiority or other test); Placebo vs GW823093C 15 mg; Mean Difference (Final Values) 3.87 (95% CI 2.33 to 5.41); Double-delta analysis NCT00372957 ↗
registry analysis (superiority or other test); Placebo vs GW823093C 15 mg; Mean Difference (Final Values) -1.56 (95% CI -6.00 to 2.89); Double-delta analysis NCT00372957 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GW823093 | Unknown | 15 mg | Oral |
| Subject | GW823093 | Unknown | 30 mg | Oral |